Health plan pharmacists are in the perfect position to see overprescribing as it happens.
An astonishing 25% of Americans ages 65 to 69 take at least 5 prescription drugs to treat chronic conditions; among people ages 70 to 79, the number is 46%. Add in nonprescription medications and you’ll find that44% of men and 57% of women older than 65 take 5 or more medications per week. 12% take 10 or more.
At best, polypharmacy can be wasteful and unnecessary. At worst, it can open up a dangerous gateway to adverse drug interactions, multiple coinciding side effects, and other issues that can lead to death. Though most of us would probably prefer to focus on the clinical effects of polypharmacy, we must admit that it’s also expensive. In addition to the price of the drugs themselves, researchers say the costs associated with treating adverse drug interactions could soar to $60 billion over the next decade.
Knowing that medication overload is a real problem, many well-intentioned people have raised their voices and called on physicians to do more to fix it. But maybe physicians shouldn’t be the only ones responsible for reducing polypharmacy. In fact, maybe that burden should fall—at least in part—to health plans.
The Rise of Polypharmacy
The reasons behind the rise in drug overload among older people are manifold and have been detailed before, but understanding the drivers of the problem is crucial to finding solutions to it. Here’s how we got here:
None of these trends is new. Researchers first reported an alarming rise in polypharmacy among older adults in the first part of this century. Since then, a plethora of articles has examined the problem and its causes. The proposed solution always seems to be the same: more physician guidelines. But physicians are already awash in prescribing guidelines; in fact, Medicare requires them to conduct an Annual Wellness Visit, at which medications are supposed to be reviewed. Clearly the guidelines aren’t working. And why would they? As I described above, the polypharmacy problem among older adults is ingrained in our healthcare system. Heaping evermore standards, checklists, and guidelines onto overburdened physicians will not fix it.
A Different Approach
Short of reconfiguring the American healthcare system—or, indeed, the world’s—a better approach is to shift some of the burden of avoiding harmful drug interactions and unnecessary prescribing from physicians to health plans. As the chief pharmacy officer for SCAN, a Medicare Advantage plan that provides coverage to more than 220,000 mostly senior members, I know that plan pharmacists are in the perfect position to champion medication guideline use and trigger medication reviews. Consider the following:
This is not to say that health plan pharmacists should police patient prescriptions. On the contrary, prescribing should always be the responsibility of physicians, who are expertly trained to carry out that function. What I am advocating is a greater role for pharmacists—and especially health plan pharmacists—in advising physicians, guiding their prescribing behaviors and calling for annual “medication tune-ups.”
My hope, moreover, is that as such guidance is dispensed, primary care teams will make stopping or tapering medications that are unnecessary a normal practice. Yet until such a focus on deprescribing takes hold, leveraging programs—and people—already in place is the most expedient way to reduce the troubling trend of medication overload.
Author Information
Sharon K. Jhawar PharmD, MBA, BCGP, is chief pharmacy officer of SCAN Health Plan.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias
July 30th 2025Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
Read More